Physician profile
Allison Leong
NPI 1952440562
$3,305.02
in general payments reported to CMS, 2019-2025
28 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $265 · 2021: $687 · 2022: $492 · 2023: $477 · 2024: $271 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.91 | 2019-2023 | |
| Pfizer INC. | $304.62 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $244.26 | 2022-2025 | |
| Novo Nordisk INC | $244.24 | 2023-2024 | Wegovy |
| Therapeuticsmd, INC. | $199.52 | 2019-2022 | |
| Ascend Therapeutics US, LLC | $196.08 | 2020-2024 | |
| Evofem Biosciences, INC. | $176.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $130.14 | 2019 | |
| Amgen INC. | $121.62 | 2019 | |
| Agile Therapeutics, INC. | $118.41 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $113.94 | 2019-2023 | Slynd |
| Hologic Sales and Service, LLC | $112.81 | 2021-2024 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Astrazeneca Pharmaceuticals LP | $104.27 | 2019 | |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Lupin INC. | $98.77 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $74.15 | 2021-2022 | |
| Astellas Pharma US INC | $58.14 | 2024-2025 | Veozah |
| Duchesnay USA Incorporated | $46.24 | 2019 | |
| Allergan, INC. | $39.85 | 2019-2020 | |
| Avion Pharmaceuticals | $31.41 | 2019-2022 | |
| Shield Therapeutics INC | $31.39 | 2023 | Accrufer |
| Aspira Women'S Health INC | $24.64 | 2020 | |
| Amag Pharmaceuticals, INC. | $21.09 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.10 | 2019 | |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Myfembree |
| Mylan Pharmaceuticals INC. | $16.66 | 2021 | |
| Exact Sciences Corporation | $16.61 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $15.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Leong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.